The Food and Drug Administration granted DARA Biosciences Inc. (Nasdaq: DARA) Orphan Drug Designation for its chronic chemotherapy induced peripheral neuropathy treatment KRN5500. The stock price soared 58 cents to close at $3.09.
DARA Granted Orphan Drug Status
February 25, 2014 at 17:41 PM EST
